## Supplement

## Table S1. Sample selection for immunogenicity and characteristics

1 (%)	100 μg mRNA-1273	100 μg mRNA-1273	50 μg mRNA-1273
l	20	20	20
Study	Phase 3 COVE Part A (blinded)*	Phase 2/3 TeenCOVE Part A (blinded)*	Phase 2/3 KidCOVE Part 1*†
kge (years)			
Mean (range)	57.8 (22-75)	13.9 (12-17)	8.8 (6-11)
<65	10 (50)	NA	NA
≥65	10 (50)	NA	NA
≥6 and <12	NA	NA	20 (100)
≥12 and <16	NA	17 (85)	NA
≥16 and <18	NA	3 (15)	NA
Sex			
Female	10 (50)	12 (60)	8 (40)
Male	10 (50)	8 (40)	12 (60)
Race			
Asian	1 (5)	1 (5)	1 (5)
Black or African American	2 (10)	1 (5)	3 (15)
Native Hawaiian or other Pacific Islander	1 (5)	0 (0)	0 (0)
American Indian or Alaska Native	0 (0)	0 (0)	0 (0)
Multiple	0 (0)	2 (10)	0 (0)
Other	0 (0)	1 (5)	0 (0)
White	16 (80)	15 (75)	16 (80)
Ethnicity			
Hispanic or Latino	6 (30)	-	3 (15)
Not Hispanic or Latino	14 (70)	20 (100)	17 (85)

Table S2. Representativeness of the study sample

Category	Description
Age	Older individuals generally have increased susceptibility to severe disease and weaker
	immune responses to vaccines than younger individuals.
Sex and gender	Males tend to have greater susceptibility to COVID-19 infections than women and
-	women report greater side effects to COVID-19 vaccines than males.
Race or ethnicity	COVID-19 affects communities of color disproportionately in the United States.
Overall	The participants across the 3 trials in this study were generally balanced and
representativeness of	demonstrated expected ratios of males to females. Participants (or their legally
this trial	authorized representative) completed questionnaires regarding their assigned sex at
	birth and gender identity at study entry in each of the trials. Older adults generally have
	greater susceptibility to severe disease and weaker immune responses to vaccines,
	including COVID-19. While the majority of participants were white in this study, the
	proportions of racial and ethnic representations in the larger study populations were
	consistent with US demographics.